Patients with inflammatory arthritis requiring TNF inhibitor (TNFi) therapy use more non-steroidal anti-inflammatory drugs (NSAIDs) than general population controls. However, NSAID consumption is significantly reduced following the initiation of a first-line biologic drug. Patients with the highest NSAID use have worse patient-reported outcome measures but physician outcome measures are similar, which may suggest a non-inflammatory mechanism of the pain.
TNFi therapy is effective in controlling several rheumatic diseases and more specifically has been shown to reduce pain. NSAIDs are commonly used for the management and treatment of pain and stiffness in inflammatory arthritides and are the first-line treatment for axial spondyloarthritis. Dr Olafur Palsson (University Hospital Reykjavik, Iceland) et al. aimed to gain a better understanding of the consumption of NSAIDs in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing sp...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Switch to Sarilumab from Adalimumab Is Efficacious and Safe Next Article
Unacceptable Pain Is Common in Patients with Psoriatic Arthritis »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.